These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25797272)

  • 21. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
    Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
    AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Situ Hybridization Analysis of Long Non-coding RNAs MALAT1 and HOTAIR in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Chu YH; Hardin H; Eickhoff J; Lloyd RV
    Endocr Pathol; 2019 Mar; 30(1):56-63. PubMed ID: 30600442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
    Fazio N; Milione M
    Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
    Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
    Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
    Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
    J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
    Abdel-Rahman O; Fouad M
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.
    Priller M; Pöschl J; Abrão L; von Bueren AO; Cho YJ; Rutkowski S; Kretzschmar HA; Schüller U
    Clin Cancer Res; 2011 Nov; 17(21):6791-801. PubMed ID: 21918172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
    Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM
    J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
    Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
    Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
    Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
    Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells.
    Hu CJ; Wang B; Tang B; Chen BJ; Xiao YF; Qin Y; Yong X; Luo G; Zhang JW; Zhang D; Li S; He F; Yang SM
    Biochim Biophys Acta; 2015 Mar; 1849(3):290-9. PubMed ID: 25482013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1.
    Zeng J; Wang L; Li Q; Li W; Björkholm M; Jia J; Xu D
    J Pathol; 2009 Aug; 218(4):419-27. PubMed ID: 19235838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
    Khagi S; Saif MW
    JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression.
    Bi Z; Liu W; Ding R; Wu Y; Dou R; Zhang W; Yuan X; Liu X; Xiong L; Guo Z; Mao C
    Eur J Pharmacol; 2017 Feb; 796():175-189. PubMed ID: 28012972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
    Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
    Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system].
    Auernhammer CJ; Spitzweg C; Böck S; Knösel T; Bartenstein P
    Dtsch Med Wochenschr; 2019 Oct; 144(20):1390-1395. PubMed ID: 31594011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
    Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
    Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.